tbuckley/cabot-search huggingface dataset:
Fresh fruit consumption in relation to incident diabetes and diabetic vascular complications: A 7-y prospective study of 0.5 million Chinese adults
Authors: Huaidong Du, Liming Li, Derrick Bennett, Yu Guo, Iain Turnbull, Ling Yang, Fiona Bragg, Zheng Bian, Yiping Chen, Junshi Chen, Iona Y. Millwood, Sam Sansome, Liangcai Ma, Ying Huang, Ningmei Zhang, Xiangyang Zheng, Qiang Sun, Timothy J. Key, Rory Collins, Richard Peto, Zhengming Chen
Journal: PLoS Medicine (2017)

Background Despite the well-recognised health benefits of fresh fruit consumption, substantial uncertainties remain about its potential effects on incident diabetes and, among those with diabetes, on risks of death and major vascular complications. Methods and findings Between June 2004 and July 2008, the nationwide China Kadoorie Biobank study recruited 0.5 million adults aged 30–79 (mean 51) y from ten diverse localities across China. During ~7 y of follow-up, 9,504 new diabetes cases were recorded among 482,591 participants without prevalent (previously diagnosed or screen-detected) diabetes at baseline, with an overall incidence rate of 2.8 per 1,000 person-years. Among 30,300 (5.9%) participants who had diabetes at baseline, 3,389 deaths occurred (overall mortality rate 16.5 per 1,000), along with 9,746 cases of macrovascular disease and 1,345 cases of microvascular disease. Cox regression yielded adjusted hazard ratios (HRs) associating each disease outcome with self-reported fresh fruit consumption, adjusting for potential confounders such as age, sex, region, socio-economic status, other lifestyle factors, body mass index, and family history of diabetes. Overall, 18.8% of participants reported consuming fresh fruit daily, and 6.4% never/rarely (non-consumers), with the proportion of non-consumers about three times higher in individuals with previously diagnosed diabetes (18.9%) than in those with screen-detected diabetes (6.7%) or no diabetes (6.0%). Among those without diabetes at baseline, higher fruit consumption was associated with significantly lower risk of developing diabetes (adjusted HR = 0.88 [95% CI 0.83–0.93] for daily versus non-consumers, p < 0.001, corresponding to a 0.2% difference in 5-y absolute risk), with a clear dose–response relationship. Among those with baseline diabetes, higher fruit consumption was associated with lower risks of all-cause mortality (adjusted HR = 0.83 [95% CI 0.74–0.93] per 100 g/d) and microvascular (0.72 [0.61–0.87]) and macrovascular (0.87 [0.82–0.93]) complications (p < 0.001), with similar HRs in individuals with previously diagnosed and screen-detected diabetes; estimated differences in 5-y absolute risk between daily and non-consumers were 1.9%, 1.1%, and 5.4%, respectively. The main limitation of this study was that, owing to its observational nature, we could not fully exclude the effects of residual confounding. Conclusion In this large epidemiological study in Chinese adults, higher fresh fruit consumption was associated with significantly lower risk of diabetes and, among diabetic individuals, lower risks of death and development of major vascular complications.
Management of periodontal health in children: pediatric dentistry and periodontology interface
Authors: Bernadette K. Drummond, Michael G. Brosnan, Jonathan W. Leichter
Journal: Periodontology 2000 (2017)

Abstract The oral health of children and adolescents mirrors their general health. Because oral health care is often delivered in isolation from general health care, oral signs and symptoms do not always alert practitioners to their significance beyond the mouth. An important example of this is the association of a higher risk of dental caries and periodontal disease in children and adolescents with overweight, obesity and prediabetic conditions. Oral‐health practitioners need to consider the health conditions that their patients may have. This will aid in diagnosis and alert the practitioner to oral conditions that may not resolve without general health‐care intervention also. This paper reviews the more common oral conditions involving periodontal health in children and adolescents, and discusses the diagnosis of these conditions, potential associated health problems and the roles of pediatric dentistry and periodontology in the management of these conditions with the goal of children entering adulthood with healthy dentitions.
Predicting and Reducing Driving Mishaps Among Drivers With Type 1 Diabetes
Authors: Daniel J. Cox, Linda A. Gonder-Frederick, Harsimran Singh, Karen S. Ingersoll, Tom Banton, Jesse H. Grabman, Karen Schmidt, William Clarke
Journal: Diabetes Care (2017)

OBJECTIVE Two aims of this study were to develop and validate A) a metric to identify drivers with type 1 diabetes at high risk of future driving mishaps and B) an online intervention to reduce mishaps among high-risk drivers. RESEARCH DESIGN AND METHODS To achieve aim A, in study 1, 371 drivers with type 1 diabetes from three U.S. regions completed a series of established questionnaires about diabetes and driving. They recorded their driving mishaps over the next 12 months. Questionnaire items that uniquely discriminated drivers who did and did not have subsequent driving mishaps were assembled into the Risk Assessment of Diabetic Drivers (RADD) scale. In study 2, 1,737 drivers with type 1 diabetes from all 50 states completed the RADD online. Among these, 118 low-risk (LR) and 372 high-risk (HR) drivers qualified for and consented to participate in a 2-month treatment period followed by 12 monthly recordings of driving mishaps. To address aim B, HR participants were randomized to receive either routine care (RC) or the online intervention “DiabetesDriving.com” (DD.com). Half of the DD.com participants received a motivational interview (MI) at the beginning and end of the treatment period to boost participation and efficacy. All of the LR participants were assigned to RC. In both studies, the primary outcome variable was driving mishaps. RESULTS Related to aim A, in study 1, the RADD demonstrated 61% sensitivity and 75% specificity. Participants in the upper third of the RADD distribution (HR), compared with those in the lower third (LR), reported 3.03 vs. 0.87 mishaps/driver/year, respectively (P &amp;lt; 0.001). In study 2, HR and LR participants receiving RC reported 4.3 and 1.6 mishaps/driver/year, respectively (P &amp;lt; 0.001). Related to aim B, in study 2, MIs did not enhance participation or efficacy, so the DD.com and DD.com + MI groups were combined. DD.com participants reported fewer hypoglycemia-related driving mishaps than HR participants receiving RC (P = 0.01), but more than LR participants receiving RC, reducing the difference between the HR and LR participants receiving RC by 63%. HR drivers differed from LR drivers at baseline across a variety of hypoglycemia and driving parameters. CONCLUSIONS The RADD identified higher-risk drivers, and identification seemed relatively stable across time, samples, and procedures. This 11-item questionnaire could inform patients at higher risk, and their clinicians, that they should take preventive steps to reduce driving mishaps, which was accomplished in aim B using DD.com.
Response to cetuximab by ESCC PDXs directly correlate to EGFR overexpression.
Authors: Henry Li, lian Hai Zhang, Jie Yang, Jianyun Deng, Sheng Guo, Xiaohong Wang, Xuesong Huang, Jean-Pierre Wery, Jiafu Ji
Journal: Journal of Clinical Oncology (2015)

e15078 Background: Esophageal squamous cell carcinoma (ESCC) is a deadly malignance prevalent in parts of China and no target therapy option. Cetuximab, approved for treating subset of metastatic colorectal carcinoma (mCRC) and head and neck squamous cell carcinoma (HNSCC), has yet to be tested on ESCC. Patient derived xenografts (PDXs) are known to mimic original patient diseases, and thus their drug response. Methods: We created a cohort of ESCC PDXs and conducted a preclinical mouse clinical trial (MCT) assessing antitumor activity of cetuximab by randomly enrolling a cohort of 16 ESCC PDXs. We analyzed the drug activity using endpoints of both ORR (objective response rate per traditional TGI, tumor growth inhibition%, and clinical RECIST criteria) and survival per PFS (progression free survival) and OS (overall survival). Finally, we also investigated associated biomarker predictive of response through genomic profiling of these PDXs. Results: 12/16subjects responded to cetuximab with ORR of 75% per 60% TGI, with medium OS of 75 days for cetuximab vs. 46 days for control or medium PFS 59 days vs. 35 days respectively, all significant more than that in gastric carcinoma1. Microarrays/RNAseq revealed that the response is directly related to EGFR over-expression (r2=0.63, p-value <0.0003) (also gene amplification), similarity also seen in gastric adenocarcinoma1, but not in CRC2 and NSCLC3. This suggests that EGFR is an oncogenic driver for many ESCC individuals, and cetuximab could be an effective treatment option. We are currently using clinically applicable EGFR-IHC and -FISH to confirm this, enabling a companion diagnostics to guide treatment of ESCC if confirmed in the clinics. Our finding may represent the first report of the association of EGFR expression with cetuximab response in ESCC, and further prospective clinical investigation is warranted to support the expanding cetuximab indication into EGFR over-expressed ESCC. Further analysis of a cisplatin trial of the same cohort shows no activity correlation between cisplatin and cetuximab, suggesting the combination could be a good strategy for ESCC, or certuximab could be a good option for cisplatin resistant ESCC Conclusions: Cetuximab could be an effective treatment of ESCC.
Local Control and Toxicity of Adaptive Radiotherapy Using Weekly CT Imaging: Results from the LARTIA Trial in Stage III NSCLC
Authors: Sara Ramella, Michele Fiore, Sonia Silipigni, Maria Cristina Zappa, Massimo Jaus, Antonio Maria Alberti, Paolo Matteucci, Elisabetta Molfese, Patrizia Cornacchione, Carlo Greco, Lucio Trodella, Edy Ippolito, Rolando Maria D’Angelillo
Journal: Journal of Thoracic Oncology (2017)
Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
Authors: Philippe Moreau, Asher A. Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, Thierry Facon, Shaji Kumar, Cyrille Touzeau, Jaclyn Cordero, Jeremy Ross, Wijith Munasinghe, Jia Jia, Ahmed H. Salem, Joel Leverson, Paulo Maciag, Maria Verdugo, Simon J. Harrison
Journal: Blood (2016)
Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomized controlled trial comparing full surface and fractional CO <sub>2</sub> laser recipient‐site preparations
Authors: J.E. Lommerts, A.A. Meesters, L. Komen, M.W. Bekkenk, M.A. Rie, R.M. Luiten, A. Wolkerstorfer
Journal: British Journal of Dermatology (2017)

Autologous noncultured cell suspension transplantation is an effective treatment for repigmentation in segmental vitiligo and piebaldism. Full surface laser ablation is frequently used to prepare the recipient site before cell suspension transplantation, even though the optimal laser settings and ablation depth are unknown. To assess the efficacy and safety of less invasive recipient‐site preparations. In a randomized, observer‐blinded, controlled trial we compared different recipient‐site preparations before cell suspension transplantation in segmental vitiligo and piebaldism. In each patient, we randomly allocated three CO2 laser recipient‐site preparations (209 and 144 μm full surface, and fractional) and a control (no treatment) to four depigmentations. After 6 months we assessed repigmentation and side‐effects. We included 10 patients with vitiligo (n = 3) and piebaldism (n = 7). Compared with the control site, we found more repigmentation after full surface ablation at 209 μm (median 68·7%, P = 0·01) and 144 μm (median 58·3%, P = 0·007), but no repigmentation after fractional ablation (median 0·0%, P = 0·14). Superficial full surface ablation with a depth of 144 μm is an effective recipient‐site preparation before cell suspension transplantation, while fractional CO2 laser is not.
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia
Authors: Danielle M. Townsley, Phillip Scheinberg, Thomas Winkler, Ronan Desmond, Bogdan Dumitriu, Olga Rios, Barbara Weinstein, Janet Valdez, Jennifer Lotter, Xingmin Feng, Marie Desierto, Harshraj Leuva, Margaret Bevans, Colin Wu, Andre Larochelle, Katherine R. Calvo, Cynthia E. Dunbar, Neal S. Young
Journal: New England Journal of Medicine (2017)

Acquired aplastic anemia results from immune-mediated destruction of bone marrow. Immunosuppressive therapies are effective, but reduced numbers of residual stem cells may limit their efficacy. In patients with aplastic anemia that was refractory to immunosuppression, eltrombopag, a synthetic thrombopoietin-receptor agonist, led to clinically significant increases in blood counts in almost half the patients. We combined standard immunosuppressive therapy with eltrombopag in previously untreated patients with severe aplastic anemia.
Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms
Authors: Marco Ruella, Saad S Kenderian, Olga Shestova, Michael Klichinsky, J. Joseph Melenhorst, Mariusz A Wasik, Simon F. Lacey, Carl H June, Saar I Gill
Journal: Blood (2016)
Whither Radioimmunotherapy: To Be or Not To Be?
Authors: Damian J. Green, Oliver W. Press
Journal: Cancer Research (2017)

Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results in preclinical experiments and in clinical trials conducted in radiosensitive malignancies, particularly B-cell lymphomas. Two "first-generation," directly radiolabeled anti-CD20 antibodies, 131iodine-tositumomab and 90yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little utilized because of a variety of medical, financial, and logistic obstacles. Newer technologies employing multistep "pretargeting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therapeutic efficacy of radioimmunotherapy and diminished its toxicities. The dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficiently compelling to justify human clinical trials and reinvigorate enthusiasm for radioimmunotherapy in the treatment of malignancies, particularly lymphomas. Cancer Res; 77(9); 2191-6. ©2017 AACR.
Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression
Authors: Ashleigh R. Poh, Christopher G. Love, Frederick Masson, Adele Preaudet, Cary Tsui, Lachlan Whitehead, Simon Monard, Yelena Khakham, Lotta Burstroem, Guillaume Lessene, Oliver Sieber, Clifford Lowell, Tracy L. Putoczki, Robert J.J. O'Donoghue, Matthias Ernst
Journal: Cancer Cell (2017)
TCTAP A-150 Safety and Efficacy of Hybrid Platform Design Sirolimus Eluting Stent System in Percutaneous Coronary Intervention (PCI) in ST Elevation Myocardial Infarction (STEMI) Patients at 1 Year After Treatment
Authors: Louie Fischer, Anoop Mathew, Eapen Punnose
Journal: Journal of the American College of Cardiology (2017)
Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis
Authors: Nidhi Tandon, Surbhi Sidana, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Francis K Buadi, David Dingli, Amie Fonder, Suzanne R. Hayman, Miriam Hobbs, Wilson I Gonsalves, Prashant Kapoor, Yi L. Hwa, Robert A. Kyle, Nelson Leung, Ronald S. Go, John A Lust, Stephen J. Russell, Steven R. Zeldenrust, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood (2016)
Interdisciplinary periodontics: the multidisciplinary approach to the planning and treatment of complex cases
Authors: Karl M. Lyons, Ivan Darby
Journal: Periodontology 2000 (2017)

Abstract Periodontics cannot be practiced in isolation as frequently many patients have multiple dental needs or medical health issues requiring management. In addition, pathology may manifest in the periodontal tissues, and the onset and progression of periodontitis can be affected by systemic conditions, such as diabetes, and vice versa. The focus of this volume of Periodontology 2000 is interdisciplinary periodontics, and the articles included discuss the interactions and the interrelationshipbetween periodontal tissues/periodontal diseases and endodontics, fixed prosthodontics, implant dentistry, esthetics, gerodontology, radiology, orthodontics, pediatric dentistry, oral and maxillofacial surgery, oral pathology, special needs dentistry and general medicine. Previous volumes of Periodontology 2000 have covered some of the interactions between periodontal diseases and other dental disciplines, especially implant dentistry, ‘and the interaction between periodontal disease and systemic disease’, but there has not been a volume on interdisciplinary periodontics. The intention therefore is to show how and why periodontics should be interdisciplinary, as well as the benefits of an interdisciplinary approach; in addition, the potential consequences of using a discipline in isolation are discussed.
Getting to the heart of matters
Authors: Eleanor Tillett
Journal: British Journal of Sports Medicine (2017)

Welcome to the 2017 British Association of Sport & Exercise Medicine (BASEM) issue of the number one ranked journal in sports sciences/sports medicine/orthopaedics/rehabilitation. Following on from BASEM’s recent Spring Meeting we look ‘Hearts and Minds’. The heavyweight of this issue is undoubtedly the consensus paper – ‘International Criteria for Electrocardiographic Interpretation in Athletes’( see page 704 ) – by University of Washington’s Professor Jonathan Drezner and his international all-star team. The expert group met in Seattle in 2015 to develope ‘a clear guide to the proper evaluation of ECG abnormalities in athletes’. As you’ll see from the detail of this paper there is much on which to update ourselves. It’s open access so please share it using the ‘share tab’ which sits alongside every BJSM piece.

In balance to this in-depth look at elite athlete cardiac issues we have a PEDro Systematic Review …
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Authors: Elizabeth Allen, Arnaud Jabouille, Lee B. Rivera, Inge Lodewijckx, Rindert Missiaen, Veronica Steri, Kevin Feyen, Jaime Tawney, Douglas Hanahan, Iacovos P. Michael, Gabriele Bergers
Journal: Science Translational Medicine (2017)

Efficacy of antiangiogenic immunotherapy is associated with intratumoral formation of high endothelial venules.
Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder
Authors: Thomas Seisen, Maxine Sun, Stuart R. Lipsitz, Firas Abdollah, Jeffrey J. Leow, Mani Menon, Mark A. Preston, Lauren C. Harshman, Adam S. Kibel, Paul L. Nguyen, Joaquim Bellmunt, Toni K. Choueiri, Quoc-Dien Trinh
Journal: European Urology (2017)
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas
Authors: Sophie Weil, Matthias Osswald, Gergely Solecki, Julia Grosch, Erik Jung, Dieter Lemke, Miriam Ratliff, Daniel Hänggi, Wolfgang Wick, Frank Winkler
Journal: Neuro-Oncology (2017)

Primary and adaptive resistance against chemo- and radiotherapy and local recurrence after surgery limit the benefits from these standard treatments in glioma patients. Recently we found that glioma cells can extend ultra-long membrane protrusions, "tumor microtubes" (TMs), for brain invasion, proliferation, and interconnection of single cells to a syncytium that is resistant to radiotherapy. We wondered whether TMs also convey resistance to the other 2 standard treatment modalities. Patient-derived glioblastoma stemlike cell (GBMSC) lines were implanted under a cranial window in mice. Longitudinal in vivo two-photon laser scanning microscopy was used to follow tumor growth, including the fate of single glioma cells over months. After a cylindrical surgical lesion, GBMSCs increasingly extended TMs toward the lesion area, which contributed to the repopulation of this area over many weeks. In fact, an excessive "healing response" was observed in which tumor cell densities significantly exceeded those of unlesioned brain regions over time. Inhibition of TM formation and function by genetic targeting of growth associated protein-43 robustly suppressed this surgery-induced tumor growth reaction, in contrast to standard postsurgical anti-inflammatory treatment with dexamethasone. After one cycle of temozolomide chemotherapy, intra- and intertumoral heterogeneity of TM formation and interconnection was strongly associated with therapy response: when tumor cells were integrated in TM networks, they were more likely to resist chemotherapy. TMs can contribute to the resistance against standard treatment modalities in gliomas. Specific inhibition of TMs is a promising approach to reduce local recurrence after surgery and lower resistance to chemotherapy.
Sensitivity of microcavity array system for circulating tumor cells in lung cancer patients.
Authors: Hirotsugu Kenmotsu, Masahito Hosokawa, Yasuhiro Koh, Tomoko Yoshino, Takayuki Yoshikawa, Tateaki Naito, Toshiaki Takahashi, Haruyasu Murakami, Yukiko Nakamura, Asuka Tsuya, Takehito Shukuya, Akira Ono, Hiroaki Akamatsu, Reiko Watanabe, Sachiyo Ono, Masahiro Endo, Yoshihito Kikuhara, Hisashige Kanbara, Tadashi Matsunaga, Nobuyuki Yamamoto
Journal: Journal of Clinical Oncology (2012)

e21007 Background: Epithelial Cell Adhesion Molecule (EpCAM)-based enumeration of circulating tumor cells (CTCs) has prognostic value in solid tumors such as advanced breast, colon and prostate cancers. However, poor sensitivity has been reported in non-small cell lung cancer (NSCLC). We have developed a microcavity array (MCA) system integrated with a microfluidic device for recovery and enumeration of CTsC, regardless of EpCAM expression level. This system can isolate tumor cells on the basis of differences in size and deformability between tumor and hematologic cells. Methods: Paired peripheral blood samples were collected from metastatic lung cancer patients. CTCs were enumerated by EpCAM-based immunomagnetic capture (CellSearch, Veridex) and by the MCA system. In the MCA system, trapped cells were stained with Hoechst 33342, FITC-labeled anti-pan cytokeratin antibodies and PE-labeled anti-CD45 antibodies for subsequent imaging analysis. CTCs were defined as cells with round to oval morphology, a visible nucleus, positive staining for pan-cytokeratin and negative staining for CD45. We evaluated the sensitivity of the MCA system for detecting CTCs in lung cancer patients compared with the CellSearch system. Results: Twenty-two metastatic NSCLC patients and 13 small-cell lung cancer (SCLC) patients were enrolled into this study between April 2011 and January 2012. CTCs were detected using the MCA system in 17 of 22 NSCLC patients (count ≥1 per 7.5 ml) compared with 9 of 22 patients using CellSearch (p=0.013). On the other hand, CTCs were detected using MCA in all 13 SCLC patients compared with just 9 of 13 patients using CellSearch (p=0.012). More CTCs from NSCLC patients were detected by the MCA system (median 13, range 0-313 cells/7.5ml) than by the CellSearch system (median 0, range 0-37 cells/7.5ml) demonstrating statistical superiority (p=0.002, Wilcoxon test). Conclusions: Our results suggest that the MCA system is potentially superior to the CellSearch system for detecting CTCs in lung cancer patients and further clinical development should be considered.
Spinal manipulation produces modest improvements in acute low back pain
Authors: Jacqui Wise
Journal: BMJ (2017)

Spinal manipulation therapy for acute low back pain is associated with modest improvements in pain and function, according to a systematic review and meta-analysis published in JAMA .1

The authors said that the size of the benefit of spinal manipulation therapy for acute low back pain is about the same as the benefit from non-steroidal anti-inflammatory drugs.

There are a number of treatments …